The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.
On 22 June 2021, ImmunoIVD officially joined the European Alliance for Newborn Screening in SMA as our 13th Member Company. Our European Alliance for Newborn Screening in SMA demands that by 2025, newborn screening programmes in all European countries include a test for spinal muscular atrophy for all newborn children. ImmunoIVD is a Swedish company […]
Join us in celebrating! Maarssen, Netherlands; Brussels, Belgium; Delft, Netherlands. The first International Neonatal¹ Screening Day (INSD) provides a unique opportunity to celebrate the vision of those who have pioneered and expanded neonatal screening programmes and will, in turn, encourage a new generation of doctors, scientists and policy makers to extend these benefits to more […]
It’s time for Europe to bridge the newborn screening gap and include spinal muscular atrophy! The European Alliance for Newborn Screening in Spinal Muscular Atrophy calls upon the government of Europe to include a test for spinal muscular atrophy in national newborn screening programmes. Worldwide newborn screening projects and programmes for SMA clearly […]
SMA Europe launched a Europe-wide survey, aimed at understanding the treatment expectations of people living with SMA, the realities of daily living, as well as their access to clinical trials and therapy. An understanding of how these expectations may vary with parameters such as age and disease severity was also sought. How we did this […]
“There is no more time to waste for babies born with SMA – newborn screening programmes for SMA in all European countries no later than 2025” Join us for this virtual event on: When? 26 March 2021 between 12:00–13:00 CET Where? Online through Webex: https://de308142546.my.webex.com/de308142546.my/j.php?MTID=md6a8d7e9e3f65923a483ac5a32a8d39d (no registration required) Access code: 181 720 9509 Password: nbs2021 […]